معرفی
Overview
Hans Clevers is a Dutch molecular geneticist and stem cell biologist renowned for pioneering research in stem cell biology, organoid technology, and cancer genetics. He currently serves as Head of Pharma Research and Early Development (pRED) at Roche (Basel) since 2022, while maintaining an advisory role at the Hubrecht Institute. Formerly, he held key positions including Director of the Hubrecht Institute (2002–2012), Professor of Molecular Genetics at Utrecht University Medical Center, and President of the Royal Netherlands Academy of Sciences (2012–2015).
Education & Training
- M.Sc. Biology (1982), Utrecht University
- M.D. (1984), Utrecht University
- Ph.D. (1985), Utrecht University
- Postdoctoral Fellow at Dana-Farber Cancer Institute, Harvard Medical School (1985–1989)
Research Focus
His work centers on Lgr5 stem cells, Wnt signaling pathways, and their roles in cancer and tissue regeneration. Key contributions include:
- Identification of Lgr5 as a universal stem cell marker in multiple tissues
- Development of organoid culture systems for modeling human organs and diseases
- Elucidation of Wnt signaling's role in colorectal cancer initiation
Awards & Honors
Recipient of over 30 major awards, including:
- Spinoza Prize (2001) – Netherlands' highest scientific honor
- Breakthrough Prize in Life Sciences (2013)
- Heineken Prize for Medicine (2012)
- Election to National Academy of Sciences (USA, 2014)
Labs & Collaborations
Pioneer of the Hubrecht Institute's Organoid Group, now the Clevers Group, which generates organoid biobanks for personalized medicine. Collaborates globally with institutions like the Francis Crick Institute and Weizmann Institute.
